1
|
Daripelli S, Molgara P, Muddana N, Jayarajan P, Mekala VR, Reballi V, Achanta PK, Nirogi R. 005 Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist in animal models of sleep disorders. Sleep 2021. [DOI: 10.1093/sleep/zsab072.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness, sudden attacks of sleep and sometimes accompanied by cataplexy. Although the orexin deficiency is considered to be the primary cause of this disorder, lot of attention has been diverted on targeting histaminergic neurotransmission by blockade of histamine H3 receptor (H3R). Samelisant (SUVN-G3031) is one of the potent and selective H3R inverse agonist currently being evaluated in a Phase 2 study as monotherapy for the treatment of narcolepsy with and without cataplexy (ClinicalTrials.gov Identifier: NCT04072380). In the current research work, Samelisant was evaluated for neurotransmitter changes in rats and sleep EEG in orexin knockout mice, a reliable proof-of-concept study for treatment of excessive daytime sleepiness and cataplexy in narcolepsy.
Methods
Binding affinity of Samelisant towards human and rat histamine H3R was evaluated in in-vitro radioligand binding assay and functionality in GTP□S assay. Effect of Samelisant was studied in (R)-α-methyl histamine induced dipsogenia. In rat brain microdialysis, Samelisant was evaluated for its effects on modulation of neurotransmitters like histamine, dopamine and norepinephrine. Male orexin knockout mice were implanted with telemetric device for simultaneous monitoring of electroencephalography (EEG) and electromyography. Effects of Samelisant (3 and 10 mg/kg, p.o.) were evaluated during active period of animals.
Results
Samelisant is an inverse agonist at histamine H3 receptors with hKi of 8.7 nM and showed minimal binding against over 70 target sites. Samelisant produced significant increase in histamine, dopamine and norepinephrine levels in cortex. Samelisant produced no change in the striatal and accumbal dopamine levels in rats, suggesting no propensity to induce abuse liability. Samelisant blocked R-α-methyl histamine induced water intake and produced dose dependent increase in tele-methylhistamine levels in various brain regions and in cerebrospinal fluid of male Wistar rats. Samelisant produced significant increase in wakefulness with concomitant decrease in non-rapid eye movement sleep in orexin knockout mice. Samelisant also significantly decreased number of cataplectic episodes in orexin knockout mice.
Conclusion
Samelisant is an inverse agonist at histamine H3 receptor and results from the preclinical studies presented here provide a strong evidence for the potential utility of Samelisant in the treatment of narcolepsy with and without cataplexy.
Support (if any):
Collapse
|
2
|
Benade V, Daripelli S, Petlu S, Subramanian R, Bhyrapuneni G, Shinde A, Rasheed M, Jayarajan P, Choudakari P, Nirogi R. 0008 SUVN-G3031, A Histamine H3 Receptor Inverse Agonist Produces Robust Wake Promoting and Anticataplectic Activity in Orexin Knockout Mice. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, sleep paralysis, hallucinations, and in some cases episodes of cataplexy. Results from animal studies indicate the involvement of deficient orexin transmission in narcolepsy which can be circumvented by the activation of histaminergic neurons. SUVN-G3031 is a potent and selective histamine H3 receptor inverse agonist with hKi of 8.7 nM and shows less than 50% inhibition at 1 µM against 70 other targets. SUVN-G3031 exhibited excellent pharmacokinetic properties and brain penetration in preclinical species. Oral administration of SUVN-G3031 produces significant increase in histamine, dopamine and norepinephrine levels in the rat cortex. Long-term safety studies in animals have been successfully completed without any concern for further development of SUVN-G3031. In the present study, the effects of SUVN-G3031 were evaluated in orexin knockout mice, a reliable animal model of narcolepsy as a proof-of-concept study for the treatment of narcolepsy with and without cataplexy.
Methods
Male orexin knockout mice (10 - 15 weeks old, 25 - 35 g at the time of surgery) were implanted with telemetric device for simultaneous monitoring of electroencephalography (EEG) and electromyography. Animals were allowed surgical recovery of 3 weeks prior to EEG recording. Effects of SUVN-G3031 (3 and 10 mg/kg, p.o.) were evaluated during active period of animals.
Results
SUVN-G3031 produced significant increase in wakefulness with concomitant decrease in non-rapid eye movement sleep in orexin knockout mice. SUVN-G3031 also significantly decreased the number of cataplectic episodes in orexin knockout mice.
Conclusion
Results from the current preclinical study provide a strong basis for the utility of SUVN-G3031 for the treatment of narcolepsy with and without cataplexy. SUVN-G3031 is currently being evaluated in a Phase 2 study as monotherapy for the treatment of narcolepsy with and without cataplexy (ClinicalTrials.gov Identifier: NCT04072380).
Support
None
Collapse
Affiliation(s)
- V Benade
- Suven Life Sciences, Hyderabad, INDIA
| | | | - S Petlu
- Suven Life Sciences, Hyderabad, INDIA
| | | | | | - A Shinde
- Suven Life Sciences, Hyderabad, INDIA
| | - M Rasheed
- Suven Life Sciences, Hyderabad, INDIA
| | | | | | - R Nirogi
- Suven Life Sciences, Hyderabad, INDIA
| |
Collapse
|
3
|
Daripelli S, Benade V, Tirumalasetty C, Subramanian R, Petlu S, Badange R, Nirogi R. SUVN-G3031, A histamine H3 receptor inverse agonist produces wake promoting and anti-cataplectic effects in hypocretin-2-saporin lesioned rats. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Benade V, Bhyrapuneni G, Abraham R, Medapati RB, Daripelli S, Kamuju V, Gandipudi S, Tirumalasetty C, Bojja K, Manchineella S, Nirogi R, Jasti V. P3-042: SUVN-502: A PURE 5-HT 6
ANTAGONIST POTENTIATES THE EFFECTS OF DONEPEZIL OR MEMANTINE IN ANIMAL MODELS OF COGNITION, NEUROCHEMISTRY AND ELECTROPHYSIOLOGY. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.3068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Benade V, Daripelli S, Tirumalasetty C, Subramanian R, Petlu S, Badange R, Nirogi R. 0054 SUVN-G3031, a Histamine H3 Receptor Inverse Agonist Produces Wake Promoting Effect in Orexin-2-saporin Lesioned Rats. Sleep 2019. [DOI: 10.1093/sleep/zsz067.053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Daripelli S, Kamuju V, Gandipudi S, Tirumalasetty C, Benade V, Bhyrapuneni G, Nirogi R. P2‐234: CORRELATION OF NEUROTRANSMITTER MODULATIONS AND NEURONAL OSCILLATIONS IN RAT BRAIN. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
7
|
Bhyrapuneni G, Daripelli S, Kamuju V, Benade V, Irappanavar SM, Gandipudi S, Tirumalasetty C, Petlu S, Subramanian R, Jayarajan P, Shinde AK, Nirogi R. P3‐273: NEUROCHEMICAL AND ELECTROPHYSIOLOGICAL CHARACTERIZATION OF SUVN‐I6107, A NOVEL MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
8
|
Bhyrapuneni G, Daripelli S, Benade V, Muddana N, Goyal V, Pandey SK, Nirogi R. Rat Video-Electroencephalography as a Model to Assess Early Stage Safety Assessment of Sleep Disturbance and Seizurogenic Potential. J Pharmacol Toxicol Methods 2017. [DOI: 10.1016/j.vascn.2017.09.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Benade V, Daripelli S, Ayyanki G, Kamuju V, Gandipudi S, Tirumalasetty C, Bhyrapuneni G, Nirogi R. [P2–217]: CORRELATION OF ACETYLCHOLINE LEVELS WITH NEURONAL OSCILLATIONS IN THE BRAIN: A PRECLINICAL COMPARISON STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Abraham R, Shinde AK, Goyal VK, Pandey SK, Medapati RB, Yathavakilla S, Tadiparthi J, Edula S, Subramanian R, Mekala VR, Muddana N, Uthukam V, Daripelli S, Devarapalli B, Eeda R, Nirogi R. P3‐135: SUVN‐I4035 ‐ Preclinical Characterization of Novel Muscarinic M1 Positive Allosteric Modulator. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.1794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Benade VS, Daripelli S, Thentu JB, Manoharan A, Medapati RB, Subramanian R, Mekala VR, Shinde AK, Badange RK, Goyal VK, Pandey SK, Nirogi R. P1‐310: Suvn‐g3031, an h
3
receptor inverse agonist, produces procognitive effects without affecting sleep in preclinical models. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.525] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|